Next Article in Journal
Differential Anxiety Responses in Acute Myocardial Infarction vs. COVID-19 Pneumonia Patients
Previous Article in Journal
Posterior-Only T11 Vertebral Column Resection for Pediatric Congenital Kyphosis Surgical Correction
Previous Article in Special Issue
Differential Effects of Intra-Abdominal Hypertension and ARDS on Respiratory Mechanics in a Porcine Model
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 60
Issue 6
10.3390/medicina60060901
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Clinical Profiles, Laboratory Biomarkers, and Mortality in Cancer Patients with Lower Respiratory Tract Infections: A Prospective Cohort Study

by
Samah Radwan
1,
Dalia F. Mourad
1,
Rana Hamdy
2,
Mahmoud M. Kamel
1,
Ahmed S. Abdel-Moneim
3,*,
Dina M. Elkhashab
1 and
Dalia Y. Kadry
1,*
1
Clinical Pathology Department, National Cancer Institute, Cairo University, Cairo 12613, Egypt
2
Pediatric Oncology Department, National Cancer Institute, Cairo University, Cairo 12613, Egypt
3
Department of Microbiology, College of Medicine, Taif University, Al-Taif 21974, Saudi Arabia
*
Authors to whom correspondence should be addressed.
Medicina 2024, 60(6), 901; https://doi.org/10.3390/medicina60060901
Submission received: 5 May 2024 / Revised: 26 May 2024 / Accepted: 27 May 2024 / Published: 29 May 2024
(This article belongs to the Special Issue Current Concepts and Advances in Respiratory and Emergency Medicine)
Versions Notes

Abstract

:
Respiratory tract infections (RTIs) pose a substantial health burden worldwide, especially among immunocompromised groups like cancer patients. The aim of this prospective cohort study was to explore lower respiratory tract infections in cancer patients. We followed 107 cases with clinically or radiologically suspected lower respiratory tract infections until discharge or death, comprising 65 males and 42 females across diverse age groups. Clinical evaluations, including patient history, examination, and malignancy diagnosis, were conducted. Nasopharyngeal swabs (NPSs), sputum samples, and blood samples were collected within 24 h of symptom onset. Multiplex Real-Time PCR allowed for the simultaneous detection of viral, bacterial, and fungal infections, while conventional microbiological culture methods were used for bacterial and fungal analysis. SARS-CoV-2 infection was excluded in all of the enrolled patients using real-time RT-PCR. Hematological and biochemical analyses included hemoglobin, lymphocyte, neutrophil, and platelet counts, along with ALT, AST, creatinine, and CRP levels. Significant differences were noted in clinical presentations, management outcomes, and prognostic markers among patients with different hematological malignancies. Distinct clinical profiles were identified for leukemia, lymphoma, and solid tumors, with variations in age distribution and symptom prevalence. ICU admission rates varied significantly, with solid tumor patients exhibiting higher rates. The hematological and biochemical biomarkers differed across malignancies, with notable associations between lymphopenia, thrombocytopenia, and mortality following respiratory episodes. This study highlights the critical role of rapid pathogen detection and infection control measures in safeguarding vulnerable cancer patients from nosocomial transmission.

1. Introduction

Respiratory tract infections (RTIs) represent a significant health burden globally, particularly among immunocompromised populations such as cancer patients. Lower respiratory tract infections (LRTIs), including pneumonia and bronchitis, pose serious challenges in management due to their potential for severe complications and adverse outcomes. Cancer patients, with their compromised immune systems and susceptibility to infections, are particularly vulnerable to LRTIs. The immunosuppressive effects of cancer treatments further exacerbate this vulnerability, making early diagnosis and prompt management crucial for improving patient outcomes [1,2,3,4].
Cancer patients often present with nonspecific respiratory symptoms, including fever, cough, dyspnea, and chest pain. However, distinguishing between respiratory tract infections and cancer progression or treatment-related complications can be challenging. This highlights the importance of comprehensive clinical assessment and microbiological investigations to identify the underlying etiology and guide appropriate treatment strategies [5,6,7].
Various pathogens, including bacteria, viruses, fungi, and opportunistic microorganisms, can cause LRTIs in cancer patients. Common bacterial pathogens implicated in pneumonia include Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus. Viral respiratory pathogens, such as influenza viruses, respiratory syncytial virus (RSV), and adenovirus, are also significant contributors to LRTIs, particularly in immunocompromised individuals. Moreover, opportunistic fungal infections, such as invasive aspergillosis and Pneumocystis jirovecii pneumonia (PCP), pose a considerable risk to cancer patients undergoing chemotherapy or stem cell transplantation [8,9,10,11].
Despite advancements in diagnostic techniques, challenges remain in accurately identifying the causative pathogens of LRTIs in cancer patients. Molecular methods, including polymerase chain reaction (PCR) assays, offer sensitive and specific detection of viral and atypical bacterial pathogens. However, conventional microbiological cultures are still necessary for identifying antibiotic-resistant bacteria and guiding antimicrobial therapy. Additionally, the interpretation of microbiological results in cancer patients can be complex due to the presence of colonization, environmental contamination (e.g., from hospital surfaces, medical equipment, and healthcare personnel), bacterial biofilms, and previous antimicrobial exposure [12,13].
The clinical management of LRTIs in cancer patients involves a multidisciplinary approach, including antimicrobial therapy, supportive care, and, in severe cases, intensive care unit (ICU) admission and mechanical ventilation. The early initiation of empirical antibiotics is essential for reducing mortality in cancer patients with suspected bacterial pneumonia. However, antimicrobial stewardship is critical to prevent the emergence of multidrug-resistant pathogens and opportunistic infections. Furthermore, supportive measures, such as supplemental oxygen therapy, bronchodilators, and chest physiotherapy, play a vital role in alleviating respiratory symptoms and preventing complications [14,15].
Despite significant progress in understanding the epidemiology and clinical management of LRTIs in cancer patients, several gaps exist in our knowledge. These include the optimal diagnostic approach for identifying respiratory pathogens, the role of novel biomarkers in predicting disease severity and treatment response, and the impact of emerging infectious threats, such as COVID-19, on cancer patients’ outcomes. Addressing these gaps requires collaborative research efforts, incorporating clinical data, microbiological findings, and immunological parameters to tailor interventions to the unique needs of cancer patients with respiratory infections.
The aim of the present prospective cohort study was to investigate the clinical characteristics, microbiological etiology, and management outcomes of lower respiratory tract infections in cancer patients. Specifically, the authors sought to characterize the clinical presentation and disease severity of LRTIs in cancer patients and evaluate the utility of hematological and biochemical biomarkers in predicting disease progression and clinical outcomes in cancer patients with LRTIs.

2. Materials and Methods

2.1. Sample Collection and Processing

This study obtained approval from the Institutional Review Board of Cairo University’s National Cancer Institute (Approval No. 2207-310-031, dated 22 July 2022). This prospective cohort investigation screened all hospitalized individuals from the medical oncology and pediatric oncology departments at the National Cancer Institute, Cairo University, from 1 April 2023 to 31 August 2023, for lower respiratory tract infections. A total of 107 cancer patients, suspected clinically or radiologically of lower respiratory tract infection, were observed until discharge or death. The cohort consisted of 65 males and 42 females, spanning ages from under 1 year to over 60 years old. The cancer patients included 75 initial cancer cases, and 32 were follow-up cancer cases. Each participant underwent a thorough clinical evaluation, encompassing medical history, clinical examination, and complete diagnosis to determine the type of malignancy. In addition to blood samples, nasopharyngeal swabs were collected, mainly from children, while both nasopharyngeal swabs and sputum samples were collected from adult patients, all within 24 h of symptom onset. All patients were initially screened and confirmed to be free from SARS-CoV-2 viral infection.

2.2. Molecular and Classical Detection of Respiratory Infections in Cancer Patients

Multiplex Real-Time PCR, the Fast Track FTD-33 Test Kit (Fast Track Diagnostics), was used to identify respiratory tract infections comprehensively. The VERSANT® Sample Preparation 1.0 Reagents kit facilitated nucleic acid extraction, carried out via the automated APEX KING FISHER platform from Thermofisher Scientific, München, Germany. Genomic RNA isolated from respiratory specimens underwent reverse transcription using specific primers, followed by immediate polymerase chain reaction (PCR) within the same tube. Concurrently, PCR amplification occurred for various pathogens’ DNA within the same tube. All experiments were executed using the QuantStudioTM 5 Real-Time PCR system. The panel comprised 12 bacterial targets, 20 viral targets, and 1 fungal target (P. jirovecii). Among the bacterial targets were H. influenzae, Bordatella species (excluding B. parapertussis), M. catarrhalis, Salmonella species, L. pneumophila/longbeachiae, K. pneumoniae, S. aureus, S. pneumoniae, C. pneumoniae, and M. pneumoniae. On the viral spectrum, the targets encompassed influenza A, B, C, including subtype H1N1pdm09, rhinovirus, coronaviruses (NL63, 229E, OC43, HKU1), parainfluenza viruses (PIV-1–4), metapneumoviruses (A and B), bocavirus, hRSV serotypes (A and B), human adenovirus, enterovirus, and parechovirus. For routine classical microbiological examination, a second sample (nasopharyngeal swab and/or sputum) underwent immediate processing using conventional culture methods for bacteria, with automated diagnosis conducted using Vitec 2. Additionally, fungal culture was performed on Sabouraud dextrose agar.

2.3. Hematological and Biochemical Analysis

Hematological parameters, including lymphocyte, neutrophil, and platelet counts, were assessed utilizing a standardized automated hematology analyzer (SYSMEX XN-9100TM Sysmex Corporation, Kobe, Japan). The quantification of ALT, AST, and creatinine was measured using the relevant kits according to the manufacturer’s instructions (Beckman Coulter AU 680, Miami, FL, USA). CRP levels in the serum were determined using a high-sensitivity CRP assay kit (Catalog Number SE120041, Sigma-Aldrich Co., St. Louis, MO, USA). This specialized assay kit is designed to detect low concentrations of CRP.

2.4. Statistical Analysis

The investigation employed various statistical techniques, including ANOVA, Chi-square test, Kruskal–Wallis test, Mann–Whitney U test, and independent samples t-test. A multivariate analysis was conducted using the Generalized Linear Model (GLM) to analyze the mixed data, accommodating both non-parametric and parametric variables.

3. Results

3.1. Pathogens Detected in Cancer Patients with Lower Respiratory Tract Infections

Among the 107 examined patients, 48 showed bacterial infection with a single bacterial pathogen (mainly Coagulase-Negative Staphylococci and Klebsiella pneumoniae), 3 showed fungal infection (Pneumocytis jirovecii and Candida albicans), and 1 showed viral infection (H1N1pdm09). Mixed infections involving more than one pathogen were detected in 42 patients, including 16 with mixed bacterial and viral infections; 2 with mixed bacterial, viral, and fungal infections; 12 with mixed bacterial infections; and 13 with mixed bacterial and fungal infections. Meanwhile, pathogens were not detected in 11 patients using the adopted methods in the current study (Table 1). The mixed viral infection included rhinovirus, influenza B virus, influenza C virus, HCoV-229, HCoV-OC43, HCoV-KHU1, PIV-3, and PIV-4. Mixed bacterial infection included Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, Legionella pneumonia, and Moraxella catarrhalis.

3.2. The Clinical Profile and Management Outcomes of Patients with Different Hematological Malignancies

The average age differed significantly across various malignancies (p < 0.031). Individuals with solid tumors exhibited a notably higher mean age (41.42 years) compared to those with leukemia (28.30 years) and lymphoma (21.73 years). No notable variance was observed in the gender distribution among different malignancies. Various clinical indicators were examined, encompassing fever, rhinorrhea, dyspnea, tachypnea, dry cough, productive cough, crepitation, and wheezy chest. Statistically significant distinctions were noted in the prevalence of dyspnea (p < 0.062) and tachypnea (p < 0.016) among different malignancies. The percentage of patients requiring ICU admission significantly varied among malignancies (p < 0.033). However, there was no notable contrast in ICU stay duration across different malignancies. Considerably elevated rates of mechanical ventilation were observed among patients with solid tumors compared to other malignancies (p < 0.001). Nonetheless, the duration of ventilator support did not display significant differences among different malignancies (Table 2).

3.3. Comparative Analysis of Hematological and Blood Biochemical Biomarkers in Patients with Various Malignancies

Between 33 and 42% of patients with leukemia, lymphoma, and solid tumors died following an LRTI. Significant differences were observed in Hb levels among different malignancies (p < 0.001). The least significant difference (LSD) revealed significant variation between the Hb concentration in solid tumors (9.73 ± 1.72) and leukemia (8.46 ± 2.10) (p < 0.001). Similarly a significant difference was reported between lymphoma (9.43 ± 2.04) and leukemia (p < 0.05). No significant reference was detected between lymphoma and solid tumors. Highly significant variation was detected in the leukocytic count in leukemia patients in comparison to other malignancies (p < 0.001). The lymphocyte count also showed significant differences among malignancies (p < 0.001), with the highest prevalence of lymphopenia observed in patients with solid tumors (27/50, 64.3%) and the highest prevalence of lymphocytosis observed in leukemia patients (24/42, 48%). Similarly, significant differences were noted in the distribution of neutrophils among malignancies (p < 0.001), with patients with solid tumors showing the highest prevalence of neutrophilia (25/42, 59.5%), while the highest prevalence of lymphopenia was observed in leukemia patients (39/50, 78.0%). The platelet profile also varied significantly among malignancies (p < 0.001), with patients with leukemia having a higher prevalence of thrombocytopenia and those with lymphoma having a higher prevalence of thrombocytosis. Creatinine, ALT, AST, CRP, Pt, PC, and INR levels did not exhibit significant differences among malignancies (Table 3).

3.4. Impact of ICU Admission, Hematological, and Biochemical Biomarkers on Mortality Rate in Cancer Patients Following Respiratory Episodes

Following respiratory episodes that were mostly due to infections in cancer patients, 63 survived and 47 died. Notably, there was a significant difference in ICU admission between survivors and non-survivors (p = 0.001), with a higher proportion of non-survivors requiring ICU care. The duration of the ICU stay was also significantly longer for non-survivors compared to survivors (p < 0.001). Mechanical ventilation was more frequently required among non-survivors (p < 0.001), with a longer duration of ventilator support observed, although this difference was not statistically significant. Analyzing blood gas parameters, non-survivors exhibited lower pH levels compared to survivors (p < 0.006), along with higher pCO2 levels (p < 0.031). However, no significant differences were observed in pO2 levels between the two groups (Table 3).
There was a significant difference in hemoglobin (Hb) levels between survivors and non-survivors (p < 0.014). Thrombocytopenia was significantly more prevalent in non-survivors (p < 0.012), indicating a potential association with mortality. Furthermore, there were no significant differences in PT, PC, or INR between survivors and non-survivors. Neutrophil, CRP, creatinine ALT, AST, and LDH levels did not show any statistically significant differences between survivors and non-survivors (Table 4).

3.5. Multivariate Analysis of Clinical Variables and Patient Outcomes

The multivariate analysis reveals significant associations between various clinical variables and patient outcomes in the intensive care setting. The corrected model in MANOV indicates significant effects on several dependent variables, including creatinine, pH, pCO2, thrombocyte, hemoglobin (Hb), and total leukocyte count (TLC). Notably, age is significantly associated with creatinine (p = 0.038) and TLC (p = 0.041). The number of ICU stay days shows a significant impact on creatinine (p = 0.009) and thrombocyte (p = 0.025). Mechanical ventilation significantly affects C-reactive protein (CRP) (p = 0.049), alkalosis (p = 0.041), and pH (p = 0.029). Additionally, the type of tumor significantly influences the pH (p = 0.027), pCO2 (p = 0.005), neutrophil (p = 0.005), Hb (p = 0.015), TLC (p = 0.001), ALT (p = 0.012), and AST (p = 0.002) (Table 5).
The multivariate analysis of variance (MANOVA) revealed significant findings across several parameters. The corrected model significantly predicted neutrophil status (p < 0.017), hemoglobin levels (p < 0.023), total leukocyte count (TLC) (p < 0.005), and ICU stay days (p < 0.023). The intercepts for variables, such as leukocyte count, LDH, AST, creatinine, CRP, pH, and others, highlighted the significant contributions of baseline values. Furthermore, the analysis showed that ICU stay days significantly impacted fatality (p < 0.002). The type of tumor significantly influenced neutrophil counts (p < 0.002), hemoglobin levels (p < 0.020), TLC (p < 0.021), and leukocyte count (p < 0.021). Additionally, TLC influenced both fatality and the type of tumor (p < 0.034).

4. Discussion

This study offers a comprehensive understanding of how different types of hematological malignancies affect patients’ clinical profiles and management outcomes, revealing crucial insights that call for thorough examination. In our investigation, bacterial infection emerged as the most detected pathogen. Both staphylococcal species and Klebsiella pneumoniae, a well-recognized Gram-negative bacterium, have consistently been identified as significant pathogens in nosocomial infections and among cancer patients [16,17,18]. Their capacity to form biofilms and develop resistance to antibiotics adds further complexity to treatment strategies [19]. These findings are consistent with the existing literature, which highlights the heightened vulnerability of cancer patients to nosocomial infections, often attributed to their compromised immune systems and frequent exposure to healthcare environments [11,17,20].
Significant differences in the average age across different malignancies suggest demographic heterogeneity within hematological cancers. Solid tumors are linked with a notably higher mean age compared to leukemia and lymphoma, indicating potential variations in disease etiology and progression [21]. The absence of significant variance in gender distribution among different malignancies indicates that hematological cancers may affect individuals irrespective of gender. This finding aligns with prior research demonstrating comparable incidence rates among males and females for certain hematological malignancies [22,23].
The examination of various clinical indicators, such as fever, dyspnea, and cough, provides valuable insights into the symptomatology of hematological malignancies. Significant distinctions were observed in the prevalence of dyspnea and tachypnea among different malignancies, which were also reported in other previous studies [24,25]. There was significant variation in the percentage of patients requiring ICU admission across malignancies, highlighting diverse clinical trials and illness severity among hematological cancer patients. This finding emphasizes the need for tailored critical care approaches and resource allocation based on disease-specific factors and patient characteristics, as previously described [26,27].
Survival rates varied among different hematological malignancies, with leukemia, lymphoma, and solid tumors exhibiting low survival outcomes. This finding matched those reported in other studies and suggests that the type of cancer significantly influences patient prognosis [28,29].
Significant differences in hemoglobin (Hb) levels were observed across malignancies, with patients with leukemia showing the lowest mean Hb level, which agrees with other studies [30,31]. These findings assume variations in erythropoietin production, bone marrow function, and treatment-related factors such as chemotherapy-induced myelosuppression.
Variations in lymphocyte (LC) and neutrophil distribution highlight potential differences in immune responses among malignancies. The higher prevalence of lymphopenia in patients with solid tumors may indicate impaired immune function, while the higher prevalence of neutrophilia suggests an inflammatory response, characteristic of tumor microenvironments [32,33,34,35].
Platelet profiles varied significantly among malignancies, with patients with leukemia exhibiting a higher prevalence of thrombocytopenia and those with lymphoma showing a higher prevalence of thrombocytosis. These findings may reflect differences in platelet production, consumption, and the underlying pathophysiology of hematological cancers [36,37,38].
Creatinine levels exhibited significant differences among malignancies, with patients with solid tumors having the highest mean creatinine level. These variations imply differences in renal functions, tumor-related renal impairment, or nephrotoxic effects of chemotherapy [39,40,41].
The impact of ICU admission, hematological, and biochemical biomarkers on mortality rates in cancer patients following respiratory episodes reveals crucial insights into the complex interplay of clinical factors influencing patient outcomes. The significant difference in ICU admission rates between survivors and non-survivors highlights the critical role of intensive care in managing cancer patients experiencing respiratory episodes. The higher proportion of non-survivors requiring ICU care denotes the severity of respiratory complications in this subgroup, in agreement with other relevant studies [42,43,44,45,46].
Furthermore, the prolonged duration of ICU stay among non-survivors emphasizes the challenges associated with managing critically ill cancer patients, as well as the need for comprehensive and prolonged supportive care [47,48]. The longer duration of the ICU stay may also reflect the complexity of medical management and the presence of comorbidities that contribute to poorer prognosis in this patient population.
Mechanical ventilation emerged as a crucial intervention in managing respiratory failure in cancer patients, with higher frequencies observed among non-survivors [49]. Elevated rates of mechanical ventilation among patients with solid tumors denote the increased risk of respiratory complications in this subgroup. While the duration of ventilator support did not significantly differ among malignancies in the current study, the need for mechanical ventilation points out the critical nature of respiratory management in hematological cancer patients [24,47,48].
The lower pH levels and higher pCO2 levels observed in non-survivors in the current study indicate the presence of respiratory acidosis and hypoventilation, reflecting the severity of respiratory compromise and the need for aggressive ventilatory support. This emphasizes the fact that analyzing blood gas parameters provides valuable insights into the physiological derangements associated with respiratory failure [50].
Hematological and biochemical biomarkers play a crucial role in predicting mortality risk and guiding clinical management in cancer patients with respiratory episodes [51,52,53]. While no significant differences were observed in hemoglobin levels between survivors and non-survivors, lower lymphocyte counts and higher prevalence of thrombocytopenia were associated with an increased mortality risk. These findings underscore the importance of immune dysregulation and hematological abnormalities in predicting outcomes in this patient population. Furthermore, elevated levels of CRP, a marker of systemic inflammation, were significantly associated with mortality in cancer patients following respiratory episodes [54]. This highlights the role of inflammatory processes in driving disease progression and influencing patient outcomes in cancer-related respiratory complications. The MANOVA of variables in the current study indicates that leukocyte counts, neutrophil status, and hemoglobin levels particularly showed the significant impact on the fatal consequence of LRTIs and varied significantly among different types of tumors.

5. Conclusions

In conclusion, our study offers a comprehensive examination of hematological malignancies’ and solid cancer patients’ impact on patients’ clinical profiles and outcomes post-respiratory episodes. We highlight demographic heterogeneity, clinical indicator significance, and survival rate disparities across malignancies. Our findings emphasize the importance of tailored critical care interventions and personalized treatment strategies based on the cancer subtype. The association between elevated CRP levels and mortality stresses the role of inflammatory processes in disease progression.

Author Contributions

Conceptualization, D.Y.K., M.M.K., A.S.A.-M. and D.Y.K.; methodology, D.M.E., D.Y.K., S.R., D.F.M. and R.H.; validation, D.Y.K. and M.M.K.; formal analysis, D.M.E., D.Y.K., S.R., D.F.M. and R.H.; validation, D.Y.K. and M.M.K.; data curation, A.S.A.-M. and D.Y.K.; writing—original draft preparation, D.M.E. and D.Y.K.; writing—review and editing A.S.A.-M. and M.M.K.; supervision, D.Y.K. and M.M.K.; funding acquisition, A.S.A.-M. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Taif University, Saudi Arabia, Project Number (TU-DSPP-2024-125).

Institutional Review Board Statement

The study obtained approval from the Institutional Review Board of Cairo University’s National Cancer Institute (Approval No. 2207-310-031, dated 22 July 2022).

Informed Consent Statement

Informed written consent was obtained from all subjects involved in the study.

Data Availability Statement

Dataset available on request from the authors. The raw data supporting the conclusions of this article will be made available by the authors on request.

Acknowledgments

The authors acknowledge Taif University, Saudi Arabia, for funding this research, Project Number (TU-DSPP-2024-125).

Conflicts of Interest

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Simms-Waldrip, T.; Rosen, G.; Nielsen-Saines, K.; Ikeda, A.; Brown, B.; Moore, T. Invasive fungal infections in pediatric hematopoietic stem cell transplant patients. Infect. Dis. 2015, 47, 218–224. [Google Scholar] [CrossRef] [PubMed]
  2. Bay, S.B.; Kebudi, R. Respiratory viral panel testing in children with cancer and respiratory tract infections. Pediatr. Blood Cancer 2021, 68, e28773. [Google Scholar] [CrossRef] [PubMed]
  3. Zhang, D.; Jin, J.; Dou, J.; Huang, Y.; Zhang, H. Impact on hospitalization and infection patterns of advanced lung cancer with lower respiratory tract infections: Targeted therapy vs. chemoradiotherapy. Oncol. Lett. 2024, 27, 154. [Google Scholar] [CrossRef] [PubMed]
  4. Lee, M.A.; Shin, K.M.; Lim, J.K.; Cho, S.H.; Kim, H.J.; Kim, G.C.; Lee, S.M.; Yoo, S.S. Nodular tracheobronchitis in a patient with lymphoma: An unusual presentation of viridans streptococcal respiratory tract infection. Clin. Respir. J. 2018, 12, 327–330. [Google Scholar] [CrossRef] [PubMed]
  5. Abuhelwa, Z.; Alsughayer, A.; Abuhelwa, A.Y.; Beran, A.; Sayeh, W.; Khokher, W.; Sajdeya, O.; Khuder, S.; Assaly, R. In-Hospital Mortality and Morbidity in Cancer Patients with COVID-19: A Nationwide Analysis from the United States. Cancers 2022, 15, 222. [Google Scholar] [CrossRef] [PubMed]
  6. Wang, H.J.; Chen, W.; Wang, H.Z.; Zhao, H.L.; Wang, D.H.; Long, Y.; Xing, X.Z. Expert Consensus on Acute Respiratory Failure in Critically Ill Cancer Patients (2023). Chin. Med. Sci. J. Chung-Kuo I Hsueh K’o Hsueh Tsa Chih 2023, 38, 163–177. [Google Scholar] [CrossRef] [PubMed]
  7. Beniwal, A.; Singh, O.; Juneja, D.; Beniwal, H.K.; Kataria, S.; Bhide, M.; Yadav, D. Clinical course and outcomes of cancer patients admitted in medical ICU with sepsis. J. Intensive Care Soc. 2023, 24, 351–355. [Google Scholar] [CrossRef] [PubMed]
  8. Nimer, N.; Kahder, M.; Oudat, R.; Hazaima, R.; Alkaabna, A. Lower Respiratory Infections in Children With Febrile Neutropenic Leukemia: A Case in a Jordanian Hospital. Clin. Pediatr. 2023, 62, 1342–1349. [Google Scholar] [CrossRef]
  9. Hakim, H.; Dallas, R.; Zhou, Y.; Pei, D.; Cheng, C.; Flynn, P.M.; Pui, C.H.; Jeha, S. Acute respiratory infections in children and adolescents with acute lymphoblastic leukemia. Cancer 2016, 122, 798–805. [Google Scholar] [CrossRef]
  10. Riedhammer, C.; Düll, J.; Kestler, C.; Kadel, S.; Franz, J.; Weis, P.; Eisele, F.; Zhou, X.; Steinhardt, M.; Scheller, L.; et al. Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma. Ann. Hematol. 2024, 103, 1327–1332. [Google Scholar] [CrossRef]
  11. Zhang, L.; Xiao, Y.; Zhang, G.; Li, H.; Zhao, J.; Chen, M.; Chen, F.; Liu, L.; Li, Y.; Peng, L.; et al. Identification of priority pathogens for aetiological diagnosis in adults with community-acquired pneumonia in China: A multicentre prospective study. BMC Infect. Dis. 2023, 23, 231. [Google Scholar] [CrossRef] [PubMed]
  12. Camporese, A. Impact of recent advances in molecular techniques on diagnosing lower respiratory tract infections (LRTIs). Le Infez. Med. 2012, 20, 237–244. [Google Scholar]
  13. Das, S.; Dunbar, S.; Tang, Y.W. Laboratory Diagnosis of Respiratory Tract Infections in Children—The State of the Art. Front. Microbiol. 2018, 9, 2478. [Google Scholar] [CrossRef] [PubMed]
  14. Berardi, R.; Morgese, F.; Rinaldi, S.; Torniai, M.; Mentrasti, G.; Scortichini, L.; Giampieri, R. Benefits and Limitations of a Multidisciplinary Approach in Cancer Patient Management. Cancer Manag. Res. 2020, 12, 9363–9374. [Google Scholar] [CrossRef] [PubMed]
  15. Ruckdeschel, J.; Greene, J.; Sommers, K.; Karen, K.; Kufe, D.; Pollock, R.; Weichselbaum, R. Respiratory infections in patients with cancer. In Holland-Frei Cancer Medicine, 6th ed.; BC Decker: Hamilton, ON, Canada, 2003. [Google Scholar]
  16. von Eiff, C.; Proctor, R.A.; Peters, G. Coagulase-negative staphylococci: Pathogens have major role in nosocomial infections. Postgrad. Med. 2001, 110, 63–76. [Google Scholar] [CrossRef]
  17. Lin, Y.-T.; Liu, C.-J.; Fung, C.-P.; Tzeng, C.-H. Nosocomial Klebsiella pneumoniae bacteraemia in adult cancer patients—Characteristics of neutropenic and non-neutropenic patients. Scand. J. Infect. Dis. 2011, 43, 603–608. [Google Scholar] [CrossRef] [PubMed]
  18. Heilmann, C.; Ziebuhr, W.; Becker, K. Are coagulase-negative staphylococci virulent? Clin. Microbiol. Infect. 2019, 25, 1071–1080. [Google Scholar] [CrossRef] [PubMed]
  19. De Oliveira, A.; Cataneli Pereira, V.; Pinheiro, L.; Moraes Riboli, D.F.; Benini Martins, K.; Ribeiro de Souza da Cunha, M.d.L. Antimicrobial resistance profile of planktonic and biofilm cells of Staphylococcus aureus and coagulase-negative staphylococci. Int. J. Mol. Sci. 2016, 17, 1423. [Google Scholar] [CrossRef] [PubMed]
  20. Nham, E.; Huh, K.; Cho, S.Y.; Chung, D.R.; Peck, K.R.; Lee, N.Y.; Kang, C.-I. Characteristics and clinical outcomes of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae bacteremia in cancer patients. Infect. Chemother. 2020, 52, 59. [Google Scholar] [CrossRef]
  21. Smith, A.; Howell, D.; Patmore, R.; Jack, A.; Roman, E. Incidence of haematological malignancy by sub-type: A report from the Haematological Malignancy Research Network. Br. J. Cancer 2011, 105, 1684–1692. [Google Scholar] [CrossRef]
  22. Cui, X.; Zhao, X.; Liang, Y. Sex differences in normal and malignant hematopoiesis. Blood Sci. 2022, 4, 185–191. [Google Scholar] [CrossRef]
  23. Tinsley-Vance, S.M.; Durosier Mertilus, D.S.; Nodzon, L.; Lengacher, C.A. An Integrative Review of Sex Differences in Quality of Life and Symptoms Among Survivors of Hematologic Malignancies. Oncol. Nurs. Forum 2023, 50, 299–312. [Google Scholar] [CrossRef] [PubMed]
  24. Gupta, A.; Madhavan, M.V.; Sehgal, K.; Nair, N.; Mahajan, S.; Sehrawat, T.S.; Bikdeli, B.; Ahluwalia, N.; Ausiello, J.C.; Wan, E.Y.; et al. Extrapulmonary manifestations of COVID-19. Nat. Med. 2020, 26, 1017–1032. [Google Scholar] [CrossRef] [PubMed]
  25. Patel, S.A.; Minn, A.J. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity 2018, 48, 417–433. [Google Scholar] [CrossRef] [PubMed]
  26. Murawski, N.; Pfreundschuh, M. New drugs for aggressive B-cell and T-cell lymphomas. Lancet Oncol. 2010, 11, 1074–1085. [Google Scholar] [CrossRef] [PubMed]
  27. Briski, R.; Taylor, J. Treatment of Richter Transformation of Chronic Lymphocytic Leukemia in the Modern Era. Cancers 2023, 15, 1857. [Google Scholar] [CrossRef] [PubMed]
  28. Wild, C.P.; Stewart, B.W.; Wild, C. World Cancer Report 2014; World Health Organization: Geneva, Switzerland, 2014. [Google Scholar]
  29. Siegel, R.L.; Miller, K.D.; Fuchs, H.E.; Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 2022, 72, 7–33. [Google Scholar] [CrossRef]
  30. Kyriazi, V.; Theodoulou, E. Assessing the risk and prognosis of thrombotic complications in cancer patients. Arch. Pathol. Lab. Med. 2013, 137, 1286–1295. [Google Scholar] [CrossRef] [PubMed]
  31. Schulman, S.; Shrum, J.; Majeed, A. Management of bleeding complications in patients with cancer on DOACs. Thromb. Res. 2016, 140, S142–S147. [Google Scholar] [CrossRef]
  32. Swaminathan, S.; Klemm, L.; Park, E.; Papaemmanuil, E.; Ford, A.; Kweon, S.-M.; Trageser, D.; Hasselfeld, B.; Henke, N.; Mooster, J. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. Nat. Immunol. 2015, 16, 766–774. [Google Scholar] [CrossRef]
  33. Iwai, Y.; Ishida, M.; Tanaka, Y.; Okazaki, T.; Honjo, T.; Minato, N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 2002, 99, 12293–12297. [Google Scholar] [CrossRef] [PubMed]
  34. Sitlinger, A.; Brander, D.M.; Bartlett, D.B. Impact of exercise on the immune system and outcomes in hematologic malignancies. Blood Adv. 2020, 4, 1801–1811. [Google Scholar] [CrossRef] [PubMed]
  35. Carnevale, S.; Di Ceglie, I.; Grieco, G.; Rigatelli, A.; Bonavita, E.; Jaillon, S. Neutrophil diversity in inflammation and cancer. Front. Immunol. 2023, 14, 1180810. [Google Scholar] [CrossRef] [PubMed]
  36. Khorana, A.A.; Francis, C.W.; Culakova, E.; Lyman, G.H. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005, 104, 2822–2829. [Google Scholar] [CrossRef] [PubMed]
  37. Kuter, D.J. Managing thrombocytopenia associated with cancer chemotherapy. Oncology 2015, 29, 282–294. [Google Scholar] [PubMed]
  38. Crawford, J.; Herndon, D.; Gmitter, K.; Weiss, J. The impact of myelosuppression on quality of life of patients treated with chemotherapy. Future Oncol. 2024. [Google Scholar] [CrossRef] [PubMed]
  39. Aygencel, G.; Turkoglu, M.; Turkoz Sucak, G.; Benekli, M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J. Crit. Care 2014, 29, 618–626. [Google Scholar] [CrossRef] [PubMed]
  40. Travassos, P.N.C.; de Barros Silva, P.G.; Freitas, M.O.; Braga, M.D.M.; Duarte, F.B.; de Oliveira Maia, J.K.; Pitombeira, H.; de Sousa, J.H.; Alves, A.P.N.N. Risk factors for renal impairment in patients with hematological cancer receiving antineoplastic treatment. Support. Care Cancer 2022, 30, 7271–7280. [Google Scholar] [CrossRef]
  41. Salahudeen, A.K.; Doshi, S.M.; Pawar, T.; Nowshad, G.; Lahoti, A.; Shah, P. Incidence rate, clinical correlates, and outcomes of AKI in patients admitted to a comprehensive cancer center. Clin. J. Am. Soc. Nephrol. 2013, 8, 347–354. [Google Scholar] [CrossRef]
  42. Wohlfarth, P.; Staudinger, T.; Sperr, W.R.; Bojic, A.; Robak, O.; Hermann, A.; Laczika, K.; Carlström, A.; Riss, K.; Rabitsch, W. Prognostic factors, long-term survival, and outcome of cancer patients receiving chemotherapy in the intensive care unit. Ann. Hematol. 2014, 93, 1629–1636. [Google Scholar] [CrossRef]
  43. Xia, R.; Wang, D. Intensive care unit prognostic factors in critically ill patients with advanced solid tumors: A 3-year retrospective study. BMC Cancer 2016, 16, 188. [Google Scholar] [CrossRef]
  44. Heo, S.J.; Kim, G.; Lee, C.-k.; Chung, K.S.; Choi, H.J.; Sohn, J.; Lee, S. Prediction of short-and long-term survival for advanced cancer patients after ICU admission. Support. Care Cancer 2015, 23, 1647–1655. [Google Scholar] [CrossRef]
  45. Alp, E.; Tok, T.; Kaynar, L.; Cevahir, F.; Akbudak, İ.H.; Gündoğan, K.; Çetin, M.; Rello, J. Outcomes for haematological cancer patients admitted to an intensive care unit in a university hospital. Aust. Crit. Care 2018, 31, 363–368. [Google Scholar] [CrossRef] [PubMed]
  46. Bird, G.; Farquhar-Smith, P.; Wigmore, T.; Potter, M.; Gruber, P. Outcomes and prognostic factors in patients with haematological malignancy admitted to a specialist cancer intensive care unit: A 5 yr study. Br. J. Anaesth. 2012, 108, 452–459. [Google Scholar] [CrossRef] [PubMed]
  47. Liu, W.; Zhou, D.; Zhang, L.; Huang, M.; Quan, R.; Xia, R.; Ye, Y.; Zhang, G.; Shen, Z. Characteristics and outcomes of cancer patients admitted to intensive care units in cancer specialized hospitals in China. J. Cancer Res. Clin. Oncol. 2024, 150, 205. [Google Scholar] [CrossRef] [PubMed]
  48. Bryce, Y.; Hsu, M.; White, C.; Gonzalez-Aguirre, A.; Friedman, A.; Latzman, J.; Moskowitz, C.S. Peripheral Arterial Disease is Associated With Higher Rates of Hospital Encounters and Mortality in Cancer Patients: A Retrospective Study Conducted at a Tertiary Cancer Center. Curr. Probl. Cancer 2023, 47, 101015. [Google Scholar] [CrossRef] [PubMed]
  49. Azoulay, E.; Lemiale, V.; Mokart, D.; Nseir, S.; Argaud, L.; Pène, F.; Kontar, L.; Bruneel, F.; Klouche, K.; Barbier, F. Effect of high-flow nasal oxygen vs standard oxygen on 28-day mortality in immunocompromised patients with acute respiratory failure: The HIGH randomized clinical trial. JAMA 2018, 320, 2099–2107. [Google Scholar] [CrossRef] [PubMed]
  50. Young, A.Y.; Shannon, V.R. Acute respiratory distress syndrome in cancer patients. Oncol. Crit. Care 2019, 9, 557–582. [Google Scholar] [CrossRef]
  51. Yis, O.M.; Bugdayci, G.; Pehlivan, M.B.; Basol, M. Roles of the systemic inflammatory response biomarkers in the diagnosis of cancer patients with solid tumors. Exp. Biomed. Res. 2019, 2, 37–43. [Google Scholar] [CrossRef]
  52. Khalife, J.; Sanchez, J.F.; Pichiorri, F. Extracellular vesicles in hematological malignancies: From biomarkers to therapeutic tools. Diagnostics 2020, 10, 1065. [Google Scholar] [CrossRef]
  53. Tsamesidis, I.; Pantaleo, A.; Pekou, A.; Gusani, A.; Iliadis, S.; Makedou, K.; Manca, A.; Carruale, A.; Lymperaki, E.; Fozza, C. Correlation of Oxidative Stress Biomarkers and Hematological Parameters in Blood Cancer Patients from Sardinia, Italy. Int. J. Hematol. Oncol. Stem Cell Res. 2019, 13, 49–57. [Google Scholar] [CrossRef] [PubMed]
  54. Franceschi, C.; Garagnani, P.; Parini, P.; Giuliani, C.; Santoro, A. Inflammaging: A new immune-metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 2018, 14, 576–590. [Google Scholar] [CrossRef] [PubMed]
Table 1. Infection distribution and mortality rates among cancer patients with lower respiratory disease in intensive care unit.
Table 1. Infection distribution and mortality rates among cancer patients with lower respiratory disease in intensive care unit.
PathogenFatalityType of TumorCumulative
Leukemia
(N = 50)		Lymphoma
(N = 15)		Solid Tumor
(N = 42)
Not known aNon-fatal6039
Fatal1012
Single viral infectionNon-fatal0011
Fatal0000
Single Bacterial infectionNon-fatal1621028
Fatal103720
Single fungal infectionNon-fatal0202
Fatal0011
Mixed bacterial infectionsNon-fatal1113
Fatal5139
Mixed viral and bacterial infectionsNon-fatal2158
Fatal3137
Mixed viral, bacterial and fungal infectionsNon-fatal0022
Fatal0000
Mixed bacterial and fungal infectionsNon-fatal4329
Fatal1034
a No known pathogen detected. Infections were screened using FTD-33 real-time PCR commercial kit and classical bacteriological screening of bacteria and fungi.
Table 2. Comparative analysis of the clinical profile and management outcomes of patients with different malignancies.
Table 2. Comparative analysis of the clinical profile and management outcomes of patients with different malignancies.
ItemLeukemia a
N = 50		Lymphoma a
N = 15		Solid Tumor
N = 42		p Value
Age (years)28.30 ± 19.6021.73 ± 18.3741.42 ± 25.440.031 *b
Sex
 Male30 (60.0)8 (53.3)27 (64.3)0.923 b
 Female20 (40.0)7 (46.7)15 (35.7)
Clinical Signs
 Fever47 (88.7)15 (100.0)31 (79.5)0.195 b
 Rhinorrhea8 (15.1)1 (6.7)2 (5.1)0.468 b
 Dyspnea13 (24.5)7 (46.7)18 (46.2)0.062 b
 Tachypnea27 (50.9)7 (46.7)31 (79.5)0.016 *b
 Dry cough28 (52.8)10 (66.7)20 (51.3)0.748 b
 Productive cough10 (18.9)3 (20.0)13 (33.3)0.366 b
 Crepitation12 (22.6)3 (20.0)11 (28.2)0.852 b
 Wheezy chest28 (52.8)11 (73.3)20 (51.3)0.479 b
ICU admission
 No16 (32.0)4 (26.7)4 (9.5)0.033 *b
 Yes34 (68.0)11 (73.3)38 (90.5)
ICU stay (days)5.97 ± 5.108.73 ± 8.797.74 ± 8.460.849 c
Mechanical ventilation
 No46 (92.0)13 (86.7)26 (61.9)0.001 *b
 Yes4 (8.0)2 (13.3)16 (38.1)
Ventilator days6.75 ± 4.927.0 ± 4.248.76 ± 9.340.933 c
Surgical removal
 No50 (100)15 (100.0)3 (7.1)0.001 *b
 Yes0 (0.0)0 (0.0)39 (92.9)
Radiotherapy
 No50 (100)15 (100.0)27 (64.3)0.001 *b
 Yes0 (0.0)0 (0.0)15 (35.7)
pH7.41 ± 0.107.43 ± 0.067.38 ± 0.130.425 c
pCO233.94 ± 8.4234.45 ± 5.0838.58 ± 10.770.209 c
PO254.68 ± 33.3946.32 ± 20.6174.44 ± 45.500.076 c
HCO321.89 ± 3.6123.54 ± 3.7122.83 ± 4.610.551 c
a Patients with acute lymphoblastic leukemia are treated with chemotherapy according to Jude Children’s Research Hospital (SJCRH) TOTXV protocol, while patients with NHL are treated according to LMB protocol. Both b Chi square and c ANOVA test were used for statistical analysis. The mean differences and Std. Deviation. * Significant at p < 0.05. ICU: Intensive Care Unit. HCO3: Bicarbonate. PO2: Partial Pressure of Oxygen. pCO2: Partial Pressure of Carbon Dioxide. pH: Potential of Hydrogen.
Table 3. Comparative analysis of hematological and blood biochemical biomarkers in patients with various malignancies.
Table 3. Comparative analysis of hematological and blood biochemical biomarkers in patients with various malignancies.
Leukemia
N = 50		Lymphoma
N = 15		Solid Tumor
N = 42		p Value
Disease outcomes
 Alive29 (58.0)10 (66.7)25 (59.5)0.834 b
 Death21 (42.0)5 (33.3)17 (40.5)
Hb (g/dL) a8.46 ± 2.109.43 ± 2.049.73 ± 1.720.001 *c
LC54. 4 ± 101.811.1 ± 7.910.9 ± 6.70.001 c
Lymphocytes
 Lymphopenia14 (28.0)6 (40.0)27 (64.3)0.001 *b
 Normal12 (24.0)9 (60.0)10 (23.8)
 Lymphocytosis24 (48.0)0 (0.0)5 (11.9)
Neutrophils
 Neutropenia39 (78.0)4 (26.7)5 (11.9)0.001 *b
 Normal7 (14.0)4 (26.7)12 (28.6)
 Neutrophilia4 (8.0)7 (46.7)25 (59.5)
Platelet
 Thrombocytopenia44 (88.0)4 (26.7)9 (21.4)0.001 *b
 Normal6 (12.0)6 (40.0)28 (66.7)
 Thrombocytosis0 (0.0)5 (33.3)5 (11.9)
 PT (seconds)15.20 ± 3.3514.20 ± 3.5014.55 ± 2.560.522 c
 PC (%)70.56 ± 18.3679.03 ± 16.6075.7 ± 15.190.233 c
 INR1.27 ± 0.261.18 ± 0.241.21 ± 0.200.786 c
ALT (U/L)39.08 ± 73.5123.73 ± 16.7441.42 ± 53.340.593 c
AST (U/L)47.45 ± 52.1233.00 ± 23.0744.78 ± 42.640.683 c
Creatinine (mg/dL)0.78 ± 0.320.66 ± 0.260.93 ± 0.710.154 c
CRP136.99 ± 130.9679.05 ± 94.59134.3 ± 109.460.231 c
LDH (U/L)912.0 ± 1010.1865.3 ± 506.1605.8 ± 760.70.503 c
a The least significant difference (LSD) revealed significant variation between Hb concentration in solid tumor (9.73 ± 1.72) and leukemia (8.46 ± 2.10) (p < 0.001). Similarly significant difference was reported between lymphoma (9.43 ± 2.04) and leukemia (p < 0.05). Both b Chi square and c ANOVA test were used for statistical analysis. The mean differences and Std. Deviation, * Significant at p < 0.05. Hb: Hemoglobin. LC: Leukocyte count. PT: Prothrombin time. PC: Prothrombin concentration. INR: International normalized ratio. ALT: Alanine transaminase. AST: Aspartate transaminase. CRP: C-reactive protein. LDH: Lactate dehydrogenase.
Table 4. Clinical outcomes of cancer patients following lower respiratory tract infections (LRTIs).
Table 4. Clinical outcomes of cancer patients following lower respiratory tract infections (LRTIs).
VariableOutcome of Infectious Episodep Value
Alive
N = 64		Death
N = 43
ICU admission
 No24 (38.1)0 (0.0)0.001 *a
 Yes40 (61.9)43 (100.0)
ICU stay (days)4.6 ± 2.889.9± 9.40.001 *b
Mechanical ventilation
 No58 (89.1)27 (60.5)0.001 *a
 Yes6 (10.9)16 (39.5)
Ventilator days6.0 ± 4.528.78 ± 9.020.626 b
pH7.43 ± 0.077.36 ± 0.130.006 *b
pCo233.7 ± 6.7538.5 ± 11.20.031 *b
pO263.5 ± 40.863.7 ± 39.80.501 b
Hb (g/dL)9.17 ± 2.258.9 ± 1.650.014 *b
TLC46.2 ± 89.812.5 ± 23.70.001 *b
Lymphocytes
 Normal20 (38.1)11 (53.2)0.464 a
 Lymphopenia25 (38.1)22 (25.5)
 Lymphocytosis19 (30.2)10 (21.3)
Neutrophils
 Normal19 (29.7)7 (16.3)0.284 a
 Neutropenia26 (40.6)21 (48.8)
 Neutrophilia19 (29.7)15 (34.9)0.012 *a
Thrombocytes
 Normal31 (48.4)9 (20.9)
 Thrombocytopenia27 (42.2)30 (69.8)
 Thrombocytosis6 (9.4)4 (9.3)
PT (seconds)14.6 ± 2.9014.9 ± 3.090.225 b
PC (%)75.5 ± 17.072.2 ± 16.80.801 b
INR1.21 ± 0.221.25 ± 0.250.254 b
Creatinine (mg/dL)0.74 ± 0.330.94 ± 0.680.002 *b
ALT (U/L)40.3 ± 64.534.6 ± 50.10.546 b
AST (U/L)39.3 ± 44.351.5 ± 67.90.054 b
CRP110.9 ± 119.1153.0 ± 15.10.594 b
LDH (U/L)730.1 ± 845.4975.8 ± 904.430.184 b
Both a Chi square and b Student t test were used for statistical analysis. The mean differences and Std. Deviation, (*) refers to 2-tailed Sig. ICU: Intensive Care Unit. Hb: Hemoglobin. LC: Leukocyte count. PT: Prothrombin time. PC: Prothrombin concentration. INR: International normalized ratio. ALT: Alanine transaminase. AST: Aspartate transaminase. CRP: C-reactive protein. LDH: Lactate dehydrogenase.
Table 5. Multivariate analysis of variance (MANOVA) on clinical variables.
Table 5. Multivariate analysis of variance (MANOVA) on clinical variables.
SourceDependent VariableType III Sum of SquaresdfMean SquareFSig.
Corrected modelICU stay days551.917 5110.3833.9890.023
TLC73,518.166 514,703.6336.1610.005
Neutrophil10.194 52.0394.3820.017
Hb61.588 512.3183.9960.023
InterceptAge52.009152.00922.8330.000
Sex17.763117.76371.0530.000
ICU stay days993.2651993.26535.8920.000
Mechanical Ventilation0.63410.6344.8030.049
pH619.5011619.5011.090 × 1050.000
pCo214,590.580114,590.580469.0620.000
pO243,253.003143,253.00326.9960.000
HCO35170.52715170.527599.5060.000
TLC14,086.373114,086.3735.9020.032
Lymphocytes15.107115.10721.1210.001
Thrombocytes17.763117.76330.4510.000
Neutrophils6.63416.63414.2580.003
Hb1062.92611062.926344.8420.000
Pt2143.70112143.701605.6960.000
PC67,005.179167,005.179295.2890.000
INR15.455115.455551.8780.000
CRP145,320.4211145,320.4217.4590.018
LDH1.055 × 10711.055 × 1079.8290.009
AST34,268.002134,268.0026.1680.029
Creatinine6.33816.33834.5580.000
FatalityICU stay days418.7921418.79215.1330.002
Type of tumorsTLC26,090.751213,045.3765.4660.021
Neutrophil10.02625.01310.7740.002
Hb33.842216.9215.4900.020
Fatality vs. type of tumorTLC21,695.325210,847.6634.5450.034
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Radwan, S.; Mourad, D.F.; Hamdy, R.; Kamel, M.M.; Abdel-Moneim, A.S.; Elkhashab, D.M.; Kadry, D.Y. Clinical Profiles, Laboratory Biomarkers, and Mortality in Cancer Patients with Lower Respiratory Tract Infections: A Prospective Cohort Study. Medicina 2024, 60, 901. https://doi.org/10.3390/medicina60060901

AMA Style

Radwan S, Mourad DF, Hamdy R, Kamel MM, Abdel-Moneim AS, Elkhashab DM, Kadry DY. Clinical Profiles, Laboratory Biomarkers, and Mortality in Cancer Patients with Lower Respiratory Tract Infections: A Prospective Cohort Study. Medicina. 2024; 60(6):901. https://doi.org/10.3390/medicina60060901

Chicago/Turabian Style

Radwan, Samah, Dalia F. Mourad, Rana Hamdy, Mahmoud M. Kamel, Ahmed S. Abdel-Moneim, Dina M. Elkhashab, and Dalia Y. Kadry. 2024. "Clinical Profiles, Laboratory Biomarkers, and Mortality in Cancer Patients with Lower Respiratory Tract Infections: A Prospective Cohort Study" Medicina 60, no. 6: 901. https://doi.org/10.3390/medicina60060901

Article Metrics

Back to TopTop